Sebaceous Carcinoma in England (2013–2022): A national cancer registry report on incidence, referral pathways, treatment and survival

Clicks: 15
ID: 332358
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #159 of 237 articles by views in clinical and experimental dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 237 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
We present the national population-level analysis of sebaceous carcinoma (SC) in England, reporting incidence trends, referral pathways, treatment patterns, and survival between 2013 and 2022 using the National Disease Registration Service's Get Data Out dataset. SC incidence remained stable over the decade, surgery was the predominant treatment, and only one fifth of cases were identified through the urgent suspected cancer pathway. Five-year overall and net survival were lower than those reported for more common cancers, underscoring the need to improve early recognition, referral pathways, and routine MMR testing for this rare malignancy.
Reference Key
openalex_W7221808134 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Mythili Ramamurthy Srinivasan, Birgitta van Bodegraven, Sam Cook, Neil Rajan, Zoe Claire Venables
Journal clinical and experimental dermatology
Year 2026
DOI
10.1093/ced/llag446
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.